Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ALK-Abello Ord Shs Class B AKBLF

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (PINL:AKBLF)

ALK Announces U.S. FDA Approval of New AccuTest(TM) Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

PR Newswire 22 hours ago

ALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy

PR Newswire January 4, 2024

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

PR Newswire January 25, 2023

The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma

PR Newswire December 1, 2021

ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients

PR Newswire June 3, 2021

U.S. FDA Approves ALK's RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis

PR Newswire April 19, 2021

Actress and Entrepreneur JoAnna Garcia Swisher and Husband, Former MLB World Champion Nick Swisher, Join New Campaign to Empower Allergy Sufferers to Take Control of Their Allergies

PR Newswire October 28, 2020

ALK Enters into Co-Promotion Agreement with Otonomy for OTIPRIO® (ciprofloxacin otic suspension), the First and Only Single-Dose Treatment for Acute Otitis Externa (Swimmer's Ear)

PR Newswire June 17, 2020

ALK to Present New Phase 3 Data Demonstrating the Efficacy and Safety of RAGWITEK® (short ragweed pollen allergen extract tablet for sublingual use 12 Amb a 1-U) Sublingual Allergy Immunotherapy (SLIT)-Tablets in Pediatric Patients at ACAAI 2019 Annual Scientific Meeting

PR Newswire November 8, 2019

Opinion & Analysis (PINL:AKBLF)

No current opinion is available.

Bullboard Posts (PINL:AKBLF)

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse